Dixie‐Lee Esseltine

Statistics

Publications

Citations

5.8K

H-Index

Active since

2002

Affiliations

Millennium Engineering and Integration (United States)(Current)

Dana-Farber Cancer Institute

Emory University

Takeda (United States)

Cornell University

Dixie‐Lee Esseltine is an author at Millennium Engineering and Integration (United States) specializing in medicine, bortezomib-based therapy, and hematologic oncology.

Publications per year

2002–2017

Publications

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Robert Z. Orlowski, Thomas E. Stinchcombe, Beverly S. Mitchell et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +17

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Sagar Lonial, Edmund K. Waller, Paul G. Richardson et al. · Blood · 2005 · 339 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Robert Z. Orlowski, Peter M. Voorhees, Reynaldo Garcia et al. · Blood · 2004 · 319 citations

Medicine, Oncology, Pharmacology +17

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · British Journal of Haematology · 2009 · 308 citations

Medicine, Pharmacology, Pharmacotherapy +14

1–5 of 17